MarketCapExport financials
Humana (HUM)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Humana Financial Ratios 2025-2006 | HUM
Brief overview of Humana 's valuation multiples
Ratios are assessed across five available annual reports in the 2021–2025 interval.
Market valuation is represented by P/E 19.37x (median 19.37x), P/S 0.18x (median 0.42x), P/B 1.3x (median 2.76x). Multiples are on average 26.5% below their own medians. Shares look cheaper than their recent historical valuation.
The inverse P/E implies an earnings yield of 5.2%. This is not a dividend yield, but current earnings relative to market price.
Returns on assets and capital are represented by ROE 6.7%, ROA 2.4%, ROCE 15.3%. Low capital returns limit the ability to compound value internally.
On PEG (0.58x), valuation is restrained relative to growth, but one ratio cannot replace cash-flow and risk analysis.
The cash return period is stable at 6.5 days initially and 8.4 days at the end.
Overall assessment
Humana 's multiples look low against history, but fundamental returns do not yet provide convincing support.
Annual Financial Ratios Humana
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19.4 | 27.0 | 18.1 | 23.0 | 19.0 | 14.8 | 17.0 | 25.0 | 16.7 | 48.5 | 19.1 | 19.7 | 12.6 | 9.8 | 10.3 | 6.9 | 5.2 | 12.5 | - | - | |
P/S |
0.2 | 0.3 | 0.4 | 0.7 | 0.7 | 0.6 | 0.7 | 0.7 | 0.8 | 0.5 | 0.4 | 0.5 | 0.4 | 0.3 | 0.4 | 0.2 | 0.2 | 0.3 | - | - |
EPS |
9.9 | 10.0 | 20.1 | 22.2 | 22.8 | 25.5 | 20.2 | 12.2 | 16.9 | 4.1 | 8.5 | 7.4 | 7.8 | 7.6 | 8.6 | 6.5 | 6.2 | 3.9 | 5 | - |
EV (Enterprise Value) |
50 B | 60.4 B | 71.1 B | 87.1 B | 80.7 B | 66.4 B | 59 B | 55 B | 54.1 B | 40.6 B | 36.1 B | 34.5 B | 25.7 B | 21.8 B | 22.9 B | 15.1 B | 12.1 B | 14.7 B | -2.04 B | -1.74 B |
EBITDA per Share |
28.2 | 28.2 | 38.7 | 35.7 | 29.1 | 41.7 | - | - | - | - | - | - | - | - | - | 12.6 | 11.7 | 7.74 | - | - |
EV/EBITDA |
14.7 | 17.8 | 14.8 | 19.3 | 21.5 | 12.0 | - | - | - | - | - | - | - | - | - | 7.2 | 6.2 | 11.4 | -1.3 | - |
PEG |
-3.7 | - | - | - | - | 0.58 | 0.26 | -0.9 | 0.05 | -0.93 | 1.29 | -4.16 | 3.8 | -0.83 | 0.33 | - | - | - | - | - |
P/B |
1.3 | 2.0 | 2.8 | 4.2 | 3.5 | 3.6 | 3.8 | 4.1 | 4.1 | 2.8 | 2.4 | 2.3 | 1.7 | 1.4 | 1.8 | 1.1 | 0.9 | 1.8 | - | - |
P/CF |
25.0 | 11.0 | 11.3 | 14.0 | 24.7 | 8.8 | 10.1 | 27.0 | 11.6 | 21.1 | 70.5 | 20.7 | 12.1 | 7.9 | 8.4 | 3.4 | 3.8 | 8.3 | - | - |
ROE % |
6.73 | 7.37 | 15.31 | 18.33 | 18.24 | 24.53 | 22.49 | 16.56 | 24.87 | 5.75 | 12.33 | 11.89 | 13.21 | 13.81 | 17.60 | 15.87 | 18.01 | 14.52 | 20.69 | - |
ROA % |
2.43 | 2.60 | 5.29 | 6.52 | 6.61 | 9.63 | 9.31 | 6.62 | 9.01 | 2.42 | 5.16 | 4.89 | 5.94 | 6.12 | 8.01 | 6.82 | 7.35 | 4.96 | - | - |
ROCE % |
8.32 | 8.69 | 14.26 | 14.72 | 10.85 | 23.11 | - | - | - | - | - | - | - | - | - | 17.90 | 19.21 | 13.66 | 33.71 | - |
Current Ratio |
1.6 | 1.5 | 1.5 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.4 | 1.5 | 1.5 | 1.5 | 1.4 | 1.4 | 1.4 | 1.8 | 1.7 | 1.5 | - | - |
DSO |
8.4 | 7.3 | 6.4 | 6.9 | 6.5 | 5.2 | 5.9 | 6.5 | 5.8 | 8.6 | 7.8 | 8.8 | 8.4 | 6.8 | 10.2 | 9.7 | 4.9 | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Humana
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q4 | 2009-Q3 | 2009-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
1.35 | 5.78 | 9.85 | -6.6 | 1.62 | 4.52 | 10.31 | -5.75 | 3.99 | 5.63 | 6.13 | -4.280000000000001 | 6.74 | 7.7 | 9.91 | -0.07000000000000028 | 9.45 | 5.5 | 7.32 | -0.10999999999999943 | 11.91 | 4.57 | 6.42 | -2.0600000000000023 | 10.12 | 13.83 | 3.58 | 3.87 | 5.16 | 6.96 | 4.18 | 2.6 | 4.68 | 1.4 | 3.56 | 1.3 | 3.46 | 4.49 | 7.54 | -2.68 | 3.01 | 2.08 | 1.7 | 0.68 | 2.11 | 2.88 | 2.86 | 0.96 | 1.87 | 2.22 | 2.37 | -0.19 | 2.34 | 2.66 | 2.97 | 1.21 | 2.65 | 2.19 | 1.51 | 1.22 | 2.71 | 2.76 | 1.88 | 0.64 | 2.35 | 2.02 | 1.54 | 1.49 | 1.8 | 1.68 |
EBITDA per Share |
0.71 | 11.4 | 14.7 | 21.1 K | 3.43 | 9.23 | 16.8 | 13.9 K | 6.17 | 9.6 | 10.3 | 708 | 9.91 | 11.7 | 13.9 | -556 | 9.46 | 9.75 | 10.3 | -3.04 K | 5.02 | 9.72 | 9.6 | 9.26 K | 13.9 | 18.6 | 8.29 | -710 | 6.64 | 8.39 | 6.39 | -1.75 K | 7.12 | 7.84 | 6.3 | -557 | 6.07 | 7.73 | 11.9 | -7.78 | 6.47 | 4.71 | 3.81 | -1.91 K | 4.82 | 3.99 | 5.42 | -497 | 4 | 4.56 | 4.83 | -36.3 | 4.13 | 4.54 | 4.99 | -365 | 4.48 | 3.73 | 2.64 | -488 | 4.51 | 4.59 | 3.21 | -699 | 4.25 | 3.75 | 2.69 | 3.81 | 3.33 | 3.15 |
ROE % |
6.42 | 6.61 | 5.99 | 6.61 | 6.83 | 8.51 | 9.59 | 7.19 | 8.03 | 10.19 | 11.80 | 14.67 | 17.87 | 20.30 | 19.12 | 17.74 | 17.78 | 19.87 | 19.35 | 19.12 | 17.20 | 16.30 | 25.02 | 23.01 | 29.26 | 26.70 | 21.94 | 23.33 | 22.57 | 22.71 | 16.69 | 16.30 | 14.68 | 13.05 | 17.09 | 23.15 | 17.53 | 17.06 | 13.99 | 5.51 | 10.24 | 9.28 | 10.70 | 12.56 | 13.09 | 12.92 | 12.09 | 11.59 | 9.77 | 10.73 | 11.79 | 13.17 | 15.66 | 16.73 | 16.44 | 14.29 | 14.59 | 15.35 | 17.21 | 18.55 | 17.63 | 17.63 | 16.82 | 16.71 | 19.51 | 19.28 | 19.60 | 4.34 | 5.43 | 5.57 |
ROA % |
2.05 | 2.16 | 2.02 | 2.32 | 2.44 | 3.01 | 3.28 | 2.32 | 2.64 | 3.17 | 3.51 | 4.29 | 5.40 | 6.26 | 6.58 | 4.29 | 7.71 | 5.36 | 6.90 | 7.11 | 6.35 | 6.46 | 9.67 | 8.82 | 11.36 | 10.24 | 8.74 | 9.37 | 9.01 | 8.99 | 6.50 | 6.43 | 5.71 | 4.88 | 6.14 | 7.72 | 5.47 | 5.48 | 4.61 | 2.03 | 4.02 | 3.79 | 4.34 | 5.08 | 5.28 | 5.18 | 4.97 | 4.93 | 4.17 | 4.73 | 5.26 | 5.89 | 6.99 | 7.50 | 7.19 | 6.13 | 6.30 | 6.27 | 7.17 | 7.81 | 7.35 | 7.51 | 7.06 | 6.93 | 8.04 | 7.76 | 7.66 | 1.77 | 2.12 | 2.06 |
ROCE % |
6.92 | 7.88 | 7.22 | 8.15 | 8.79 | 9.93 | 10.38 | 8.32 | 8.92 | 10.89 | 12.22 | 14.33 | 16.05 | 16.31 | 19.05 | 17.35 | 17.08 | 14.60 | 12.13 | 13.18 | 11.37 | 17.03 | 22.73 | 22.62 | 26.22 | 23.29 | 18.64 | 18.37 | 19.75 | 20.89 | 22.96 | 25.28 | 25.09 | 23.78 | 21.22 | 23.29 | 17.61 | 18.36 | 16.38 | 10.08 | 14.32 | 13.15 | 12.69 | 14.24 | 14.80 | 14.16 | 15.14 | 15.19 | 12.78 | 13.55 | 13.98 | 14.58 | 16.95 | 18.26 | 18.21 | 16.26 | 16.91 | 17.64 | 19.51 | 20.86 | 19.87 | 19.90 | 18.99 | 18.90 | 21.75 | 21.05 | 20.92 | 4.78 | 5.70 | 5.68 |
Current Ratio |
1.5 | 1.5 | 1.5 | 1.6 | 1.6 | 1.6 | 1.5 | 1.6 | 1.5 | 1.5 | 1.5 | 1.5 | 1.4 | 1.4 | 1.4 | 1.6 | 1.5 | - | 1.5 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.7 | 1.6 | 1.6 | 1.7 | 1.7 | 1.7 | 1.6 | 1.7 | 1.6 | 1.7 | 1.7 | 1.6 | 1.5 | 1.5 | 1.5 | 1.7 | 1.6 | 1.7 | 1.6 | 1.7 | 1.7 | 1.7 | 1.6 | 1.7 | 1.7 | 1.8 | 1.8 | 1.8 | 1.9 | 1.8 | 1.8 | 1.8 | 1.9 | 1.7 | 1.7 | 1.8 | 1.6 | 1.8 | 1.7 | 1.8 | 1.7 | 1.7 | 1.7 | 1.7 | 1.6 | 1.6 |
DSO |
183.8 | 279.7 | 230.9 | 181.2 | 205.0 | 292.1 | 245.0 | 189.7 | 257.9 | 332.4 | 256.1 | 169.3 | 146.1 | 211.6 | 218.3 | 149.2 | 63.3 | 6.1 | 180.1 | 134.5 | 233.1 | 430.6 | 326.4 | 214.3 | 336.8 | 430.6 | 329.8 | 5.3 | 203.4 | 367.4 | 381.7 | 6.7 | 248.7 | 6.5 | 6.0 | 6.1 | 685.8 | 846.6 | 10.3 | 7.2 | 11.1 | 14.0 | 9.6 | 7.3 | 10.6 | 12.7 | 9.1 | 7.6 | 11.5 | 13.2 | 9.4 | 8.0 | 10.7 | 12.9 | 8.9 | 6.6 | 7.3 | 10.5 | 10.6 | 10.4 | 12.7 | 13.6 | 10.8 | 5.3 | - | - | 4.5 | 4.9 | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.5 | 6.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.5 | 6.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Humana , allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Health care industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Centene Corporation
CNC
|
$ 70.23 | 2.47 % | $ 34.6 B |  USA |
 |
CVS Health Corporation
CVS
|
$ 88.42 | 3.72 % | $ 112 B | USA |
 |
UnitedHealth Group Inc.
UNH
|
$ 405.09 | 1.88 % | $ 368 B | USA |
 |
Cigna Corporation
CI
|
$ 302.0 | 2.17 % | $ 79.6 B | USA |
 |
Triple-S Management Corporation
GTS
|
- | 0.28 % | $ 847 M | USA |
 |
NovoCure Limited
NVCR
|
$ 11.84 | -5.55 % | $ 1.32 B |  Jersey |
 |
Molina Healthcare
MOH
|
$ 204.87 | 0.75 % | $ 10.8 B | USA |
 |
Magellan Health, Inc.
MGLN
|
- | -0.19 % | $ 2.49 B | USA |
 |
Anthem
ANTM
|
- | -2.32 % | $ 107 B | USA |